Clinical Trials Browser

Phase 2 × Brain Neoplasms × cemiplimab × Clear all

NCT05840770 2025-05-26

Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms